Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Ernexa Therapeutics (Nasdaq: ERNA) announced the expansion of its Scientific Advisory Board into a combined Scientific and Medical Advisory Board as it prepares for clinical trials in ovarian cancer and autoimmune disease. The company has appointed two distinguished physicians: Dr. Amir Jazaeri from MD Anderson Cancer Center, who will guide the ovarian cancer program, and Dr. Anna Jonsson from the University of Colorado, who will lead translational strategy for the autoimmune pipeline.
This strategic expansion follows Ernexa's recently strengthened financial position and marks its transition from research to clinical-stage development. The enhanced advisory board will support the company's scientific and clinical strategy as it advances its first oncology and autoimmune programs toward IND-enabling studies.
Ernexa Therapeutics (Nasdaq: ERNA) ha annunciato l'ampliamento del suo Comitato Scientifico, che diventa un Comitato Scientifico e Medico congiunto, in preparazione alle sperimentazioni cliniche sul cancro ovarico e sulle malattie autoimmuni. L'azienda ha nominato due medici di spicco: Dr. Amir Jazaeri del MD Anderson Cancer Center, che guiderà il programma sul cancro ovarico, e Dr. Anna Jonsson dell'Università del Colorado, che sarà responsabile della strategia traslazionale per la pipeline delle malattie autoimmuni.
Questa espansione strategica segue il recente rafforzamento della posizione finanziaria di Ernexa e segna la sua transizione dalla ricerca allo sviluppo in fase clinica. Il comitato ampliato supporterà la strategia scientifica e clinica dell'azienda mentre procede con i suoi primi programmi oncologici e autoimmuni verso studi abilitanti IND.
Ernexa Therapeutics (Nasdaq: ERNA) anunció la ampliación de su Junta Asesora Científica, que ahora se convierte en una Junta Asesora Científica y Médica combinada, preparándose para ensayos clínicos en cáncer de ovario y enfermedades autoinmunes. La compañía nombró a dos destacados médicos: Dr. Amir Jazaeri del MD Anderson Cancer Center, quien dirigirá el programa de cáncer de ovario, y Dr. Anna Jonsson de la Universidad de Colorado, quien liderará la estrategia traslacional para la línea de enfermedades autoinmunes.
Esta expansión estratégica sigue al fortalecimiento reciente de la posición financiera de Ernexa y marca su transición de la investigación al desarrollo clínico. La junta ampliada apoyará la estrategia científica y clínica de la empresa mientras avanza con sus primeros programas de oncología y autoinmunidad hacia estudios habilitantes para IND.
Ernexa Therapeutics (나스닥: ERNA)는 난소암 및 자가면역 질환 임상 시험 준비를 위해 과학 자문위원회를 과학 및 의학 자문위원회로 확대했다고 발표했습니다. 회사는 두 명의 저명한 의사를 임명했습니다: 난소암 프로그램을 이끌 MD Anderson Cancer Center의 Dr. Amir Jazaeri와 자가면역 파이프라인의 번역 전략을 담당할 콜로라도 대학교의 Dr. Anna Jonsson입니다.
이번 전략적 확장은 최근 Ernexa의 재정적 기반 강화에 따른 것으로, 연구 단계에서 임상 단계 개발로의 전환을 의미합니다. 확대된 자문위원회는 회사가 첫 번째 종양학 및 자가면역 프로그램을 IND 승인 연구 단계로 진전시키는 데 있어 과학적 및 임상적 전략을 지원할 것입니다.
Ernexa Therapeutics (Nasdaq : ERNA) a annoncé l'élargissement de son comité consultatif scientifique en un comité consultatif scientifique et médical combiné, en vue des essais cliniques sur le cancer de l'ovaire et les maladies auto-immunes. La société a nommé deux médecins éminents : Dr Amir Jazaeri du MD Anderson Cancer Center, qui supervisera le programme sur le cancer de l'ovaire, et Dr Anna Jonsson de l'Université du Colorado, qui dirigera la stratégie translationnelle pour la pipeline des maladies auto-immunes.
Cette expansion stratégique fait suite au renforcement récent de la situation financière d'Ernexa et marque sa transition de la recherche au développement clinique. Le comité consultatif élargi soutiendra la stratégie scientifique et clinique de la société alors qu'elle fait progresser ses premiers programmes en oncologie et auto-immunité vers des études permettant l'IND.
Ernexa Therapeutics (Nasdaq: ERNA) gab die Erweiterung seines Wissenschaftlichen Beirats zu einem kombinierten Wissenschaftlichen und Medizinischen Beirat bekannt, um sich auf klinische Studien bei Eierstockkrebs und Autoimmunerkrankungen vorzubereiten. Das Unternehmen hat zwei angesehene Ärzte berufen: Dr. Amir Jazaeri vom MD Anderson Cancer Center, der das Eierstockkrebsprogramm leiten wird, und Dr. Anna Jonsson von der University of Colorado, die die translationale Strategie für die Autoimmun-Pipeline verantwortet.
Diese strategische Erweiterung folgt auf die kürzlich gestärkte Finanzlage von Ernexa und markiert den Übergang von der Forschung zur klinischen Entwicklung. Der erweiterte Beirat wird die wissenschaftliche und klinische Strategie des Unternehmens unterstützen, während es seine ersten onkologischen und autoimmunen Programme auf IND-fähige Studien voranbringt.
- Strategic expansion of advisory board with two renowned medical experts
- Recently strengthened financial position
- Progression toward clinical trials in both oncology and autoimmune programs
- Addition of expertise in gynecologic oncology and autoimmune diseases
- None.
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa’s transition from research to clinical-stage development. This comes on the heels of Ernexa’s recently strengthened financial position and is part of a broader strategy to accelerate its lead programs toward the clinic.
Joining the advisory board are two distinguished physicians: Amir Anthony Jazaeri, M.D., a leader in gynecologic oncology at The University of Texas MD Anderson Cancer Center, and Anna Helena Jonsson, M.D., Ph.D., an expert in autoimmune disease and immunology at the University of Colorado School of Medicine. Dr. Jazaeri will help guide the company’s ovarian cancer program into the clinic, while Dr. Jonsson will lead translational strategy for Ernexa’s autoimmune pipeline.
“As we prepare to advance our programs into clinical development, we’re proud to welcome renowned medical leaders to guide us,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “As we move toward key inflection points in our pipeline, their deep expertise in translational medicine and patient-centered innovation will be instrumental in advancing our lead programs. Our team is laser-focused on delivering transformative treatments for patients living with ovarian cancer and autoimmune diseases.”
The board will support Ernexa’s scientific and clinical strategy as the company advances its first oncology and autoimmune programs toward IND-enabling studies. Their expertise will inform trial design, biomarker development, and regulatory engagement.
Dr. Jazaeri is a professor of gynecological oncology at MD Anderson and is the department’s Vice Chair for Clinical Research. He is also Director of the Gynecologic Cancer Immunotherapy Program. With extensive experience in adoptive cell therapies, vaccines, and immune checkpoint inhibitors, Dr. Jazaeri has built one of the field’s most robust clinical immunotherapy programs focused on gynecologic cancers. His research also spans novel intraperitoneal therapies and tumor microenvironment profiling.
Dr. Jonsson is a physician-scientist and rheumatologist whose research at the University of Colorado Anschutz Medical Campus explores the understudied role of CD8 T cells in autoimmune diseases, particularly rheumatoid arthritis and systemic lupus erythematosus (SLE). Her work, which has included prominent roles in the NIH’s Accelerating Medicines Partnership (AMP): RA/SLE Network, leverages single-cell technologies to identify immune drivers of chronic inflammation. She also maintains an active clinical practice, ensuring that her scientific insights are closely tied to patient needs.
The company’s new advisory board structure is designed to integrate scientific discovery with clinical strategy as Ernexa advances novel cell therapies for diseases with high unmet medical needs.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Dr. Jazaeri and Dr. Jonsson receive compensation as members of the Ernexa Therapeutics medical advisory board, and this financial relationship has been disclosed to the respective organizations’ Conflict of Interest Committees in accordance with institutional policies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC, including its recent filings on Form 8-K, Form 10-K, and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
Who are the new members of Ernexa Therapeutics' (ERNA) Scientific and Medical Advisory Board?
What therapeutic areas is Ernexa Therapeutics (ERNA) focusing on for clinical development?
What is the significance of Ernexa's (ERNA) advisory board expansion in June 2025?
What will be the role of the new Scientific and Medical Advisory Board at Ernexa (ERNA)?
